Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy-Reference-Cited by-同舟云学术

Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy

Published:2018-03 Issue:4 Volume:22 Page:343-351
ISSN:1472-8222
Container-title:Expert Opinion on Therapeutic Targets
language:en
Short-container-title:Expert Opinion on Therapeutic Targets

Author:

Amatore Florent¹,Gorvel Laurent¹,Olive Daniel¹

Affiliation:

1. Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli – Calmettes, Marseille, France

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728222.2018.1444753

Reference90 articles.

1. The role of B7 family molecules in hematologic malignancy

2. A three-signal model of T-cell lymphoma pathogenesis

3. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy

4. Immune checkpoint inhibitors: a patent review (2010-2015)

5. Emerging targets in cancer immunotherapy

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotechnology Advances in Disease Treatment;International Encyclopedia of Public Health;2025

2. Identification of costimulatory molecule signatures for evaluating prognostic risk in non-small cell lung cancer;Heliyon;2024-09

3. Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer;Journal for ImmunoTherapy of Cancer;2024-08

4. Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression;Pharmaceuticals;2024-07-21

5. Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients;Journal of Surgical Oncology;2024-07-07